ArticleChemistry (Weinheim an der Bergstrasse, Germany)2020
Versatile Bispidine-Based Bifunctional Chelators for
Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Radiocopper in BCMA-targeted immunotheranostics of myeloma.Theranostics · 2026Article
- In Vitro Characterization of the Published Glypican-3-Targeting Peptide TJ12P2 Reveals a Lack of Specificity and Potency.Pharmaceuticals (Basel, Switzerland) · 2025Article
- It's a match: use of the radionuclide theranostic pairEJNMMI radiopharmacy and chemistry · 2025Article
- Metal-Ligand Interactions in Scandium Complexes with Radiopharmaceutical Applications.Inorganic chemistry · 2023Article
- Specific and safe targeting of glioblastoma using switchable and logic-gated RevCAR T cells.Frontiers in immunology · 2023Article
- Different Topologies of Hg(II)-Bispidine 1D Coordination Polymers: Dynamic Behavior in Solvent Adsorption and Exchange Processes.Chemistry (Weinheim an der Bergstrasse, Germany) · 2022Article
- Development and Functional Characterization of a Versatile Radio-/Immunotheranostic Tool for Prostate Cancer Management.Cancers · 2022Article
- Dual-Labelling Strategies for Nuclear and Fluorescence Molecular Imaging: Current Status and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Chelators for Treatment of Iron and Copper Overload: Shift from Low-Molecular-Weight Compounds to Polymers.Polymers · 2021Review
- Radiolabelled Cyclic Bisarylmercury: High Chemical and in vivo Stability for Theranostics.ChemMedChem · 2021Article
- Excited State Properties of Lanthanide(III) Complexes with a Nonadentate Bispidine Ligand.Chemistry (Weinheim an der Bergstrasse, Germany) · 2021Article
- First-Generation Bispidine Chelators forChemMedChem · 2020Article
- Versatile Bispidine-Based Bifunctional Chelators forChemistry (Weinheim an der Bergstrasse, Germany) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Bifunctional chelators as parts of modular metal-based radiopharmaceuticals are responsible for stable complexation of the radiometal ion and for covalent linkage between the complex and the targeting vector. To avoid loss of complex stability, the bioconjugation strategy should not interfere with the radiometal chelation by occupying coordinating groups. The C9 position of the very stable Cu
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.